Mandalfino P, Rice G, Smith A, Klein J L, Rystedt L, Ebers G C
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
J Neurol. 2000 Sep;247(9):691-5. doi: 10.1007/s004150070112.
There is strong circumstantial evidence that multiple sclerosis (MS) is an autoimmune disease. Nonspecific immunosuppressive therapy has not been successful in altering the natural course of the illness. Bone marrow transplantation has heretofore been a radical therapy used in patients with life-threatening malignancies but has potential as a treatment for human autoimmunity. In MS there have been no controlled studies. We report here four patients with MS undergoing bone marrow transplantation with 6-48 months of follow-up. In three this was carried out for co-existing malignancy and in one as an experimental treatment for MS using the patient's unaffected identical twin as a donor. The limited outcome that can be evaluated in these patients supports further experimentation into this treatment modality in MS patients with poor prognostic indications.
有充分的间接证据表明多发性硬化症（MS）是一种自身免疫性疾病。非特异性免疫抑制疗法未能成功改变该疾病的自然病程。骨髓移植此前一直是用于治疗危及生命的恶性肿瘤患者的一种激进疗法，但它也有作为人类自身免疫性疾病治疗方法的潜力。在MS患者中尚未进行过对照研究。我们在此报告4例接受骨髓移植的MS患者，随访时间为6至48个月。其中3例是因为同时存在恶性肿瘤而进行移植，1例是将患者未受影响的同卵双胞胎作为供体，作为MS的实验性治疗方法。在这些患者中可评估的有限结果支持对这种治疗方式在预后指征较差的MS患者中进行进一步试验。
